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Abstract 
Background: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European 
Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this 
study was to provide a comprehensive picture of the burden and unmet need of AR patients.
Methods: This was a cross-sectional, online, questionnaire-based study (June–July 2011) including symptomatic 
seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, 
residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.
Results: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with mod-
erate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer 
episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; 
p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high 
irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moder-
ate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction 
with therapy in 35.4 % of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to 
UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). 
Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 
in 5 patients) if they did not take their rhinitis medication.
Conclusions: This study differentiated between patients with mild and moderate/severe AR, demonstrating a bur-
den of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with 
what are currently considered firstline treatments suggests the need for a novel therapeutic approach.
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Background
Allergic rhinitis (AR) has been trivialized over the years, 
despite its prevalence, chronicity and the burden it 
imposes on individuals and society [1–7]. Fortunately, 
the burden of AR is now being recognised both by the 
European Academy of Allergy & Clinical Immunology 
(EAACI) as well as at the EU parliament level, in order 
to highlight the profound impact this prevalent condition 
has on the quality of life (QoL) of AR sufferers and their 
families [8, 9]. Furthermore, the Polish presidency of the 
EU has highlighted the importance of early diagnosis and 
management of allergic diseases to promote active and 
healthy ageing [10], and made this an EU priority [11, 12]. 
All of these initiatives represent a fundamental shift in 
the perception of AR.
Reports in the literature already tell us that the daily 
burden of AR symptoms can be intrusive and debilitat-
ing, negatively impacting patients’ QoL [4, 5], normal 
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activities [6, 13], well-being, cognitive functioning [14] 
even mood [15] and sleep [16]. Most AR patients attend-
ing their healthcare provider have persistent disease, with 
many using multiple therapies [17]. AR imposes a high 
socioeconomic burden, particularly in terms of indirect 
costs, including absenteeism and presenteeism (i.e. pro-
ductivity loss or under-performance at work and school) 
[18–21]. It has also been associated with poor asthma 
control; patients reporting severe rhinitis exhibit poorer 
asthma control than those with mild disease, with a nega-
tive impact equivalent to that of smoking [22].
Most AR patients visiting their physician have mod-
erate/severe disease with persistent symptoms [2, 17, 
23–25]. Insufficient symptom control by currently 
considered firstline therapies has been identified as 
a major concern [2, 4, 17], a situation which has not 
improved over time [6, 7]. Co-medication is common; 
patients self-medicate and doctors co-prescribe (anti-
histamines and intransal corticosteroids (INS) predom-
inantly) [2, 3, 23, 26, 27] despite lack of evidence for 
this strategy in the literature [28–30]. AR patients have 
high expectations from their treatment [31], but most 
are dissatisfied with the results [32, 33]. Up to 40 % of 
patients have residual moderate/severe symptoms even 
after specialized treatment [17]. Management is often 
complicated by polysensitization [13, 34], the presence 
of allergic and non-allergic disease in the same patient 
(i.e. mixed rhinitis) [35] and confounded by phenotypes 
such as severe chronic upper airway disease (SCUAD) 
[36].
Clinical trials assess patients with the most severe 
symptoms with insufficient information from observa-
tional studies to understand the differences in burden 
between mild and moderate/severe rhinitis. To date, 
many surveys on the burden of AR have been conducted 
in Europe [2–5, 25] and in the US [6, 23, 37] but no cross-
sectional questionnaire-based study, has assessed sea-
sonal AR (SAR) episode pattern and duration, medication 
and co-medication usage (and the reasons for co-medi-
cating), characterized residual symptoms on treatment 
nor provided information on healthcare visits, impact on 
asthma medication usage, absenteeism and presenteeism 
in a single study, stratified by disease severity (i.e. mild 
and moderate/severe).
The aim of this study was to describe the burden and 
unmet need of AR in one study, stratifed by disease 
severity. AR patients have been included in hundreds of 
clinical trials without a true understanding of the real 
burden of this disease, the way patients experience their 
symptoms and how they and their health care provider 
manage their disease in real-life. A secondary aim was to 
use the data obtained to inform future AR clinical trial 
design and result relevancy.
Methods
Study design
This was a cross-sectional, online, questionnaire-based 
study designed to collect representative views of peo-
ple diagnosed with SAR. It was carried out in the UK 
between June and July 2011. The survey content was 
informed by experts (see Additional file  1). Experts 
contributed to all aspects of the survey from item and 
response level development and provision of key con-
cepts to explore to provision of full UK AR medication 
listings. Ethics approval was obtained from Independ-
ent Investigational Review Board Inc., (Florida, USA). 
Concept elicitation interviews with five patients were 
conducted prior to the start of the study to establish the 
most effective way to capture data with the least patient 
burden. These interviews were designed to ensure patient 
comprehension of the questions asked. Additional infor-
mation to describe terms included in the survey were 
included based on patient advice.
Recruitment, patients and data collection
Potential participants from a UK patient panel database 
(Opinion Health) were contacted about taking part in 
the study. This is an extensive database of patients with a 
variety of medical conditions, who gave prior consent to 
be contacted for research purposes. Patients are recruited 
into the Opinion Health panel from various channels, 
including direct mailing, bespoke telephone recruitment, 
peer/healthcare provider referral, magazine/newspaper 
advertising, and from  relevant  charities/associations/
communities. The wide range of recruitment methods 
employed has led to a strong and nationally representa-
tive sample of the general population of which 18 % are 
aged over 65 years (30 % who are 55+ years), over 35 % 
are from lower household income bands with 17 % from 
Social Grade D or E.
These potential participants were provided with the 
survey address and unique identifier, which they could 
use to access the online survey. Participants who fol-
lowed the link were presented with a study screening 
form to assess their eligibility. Patients (≥18 years of age), 
currently residing in the UK, with a self-reported clini-
cal diagnosis by a medical professional of SAR and cur-
rently experiencing rhinitis symptoms, were recruited 
after informed consent. Currently symptomatic patients 
were selected to minimize recall error, enabling patients 
to draw on current symptomatic experience. Patients 
who experienced AR symptoms all year round (i.e. per-
ennial allergic rhinitis) with no seasonal flare-ups were 
excluded.
The survey was sent to 1300 potential participants. 
The aim was to recruit 1000 SAR participants, 200 mild 
and 800 moderate/severe. For the purpose of screening, 
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disease severity was graded using the ARIA-defined cri-
teria of sleep disturbance, impairment of daily activities 
including leisure/sports, impairment of work/study and 
presence of troublesome symptoms [1].
Surveys
All eligible participants were granted online access to the 
main survey to be completed at their own pace. Patients 
next completed symptom severity and socio-demo-
graphic/healthcare utilisation questionnaires (see Addi-
tional file  1). Symptom severity was assessed by EMA 
and FDA endorsed efficacy endpoints 12 h reflective total 
nasal symptom score (rTNSS; consisting of nasal conges-
tion, itching, rhinorrhea and sneezing) and 12 h reflective 
total ocular symptom score (rTOSS; comprising ocular 
itch, redness and watering). These reflective scores assess 
symptom severity for the previous 12  h. Patients rated 
all symptoms as ‘none = 0’, ‘mild = 1’, ‘moderate = 2’ or 
‘severe = 3’, both for symptoms ‘today’ and for symptoms 
‘at their worst’. Socio-demographic Information collected 
included patients’ age, gender, ethnicity and educational 
level. The healthcare resource utilisation survey included 
questions on duration and number of SAR symptom epi-
sodes, SAR medication usage, GP visits, impact on co-
morbid asthma, absenteeism and presenteeism. These 
latter two items were based on the Work Productivity 
and Activity Impairment (WPAI) questionnaire. The full 
WPAI questionnaire was not used in order to minimise 
participant burden. Symptom episode was defined for 
patients as ‘an episode is a period of time when you expe-
rience symptoms (or need to take medication to treat 
symptoms) continuously’.
Participants received £10 upon completion of the sur-
vey. All subjects were free to withdraw from participation 
in this study at any time, and for any reason.
Statistics
Statistical analyses were conducted in STATA 12 to 
compare baseline characteristics and exposures for 
mild disease to moderate/severe disease. For the pur-
pose of analysis, participants with moderate/severe AR 
were defined as those who scored a rTNSS ≥8 out of 12, 
including a congestion score ≥2/3, when describing their 
‘worst symptoms’. These rTNSS and nasal congestion 
score cut-offs were chosen in order to align with moder-
ate/severe definitions from a recently conducted clinical 
trial [38]. Participants with mild disease were the remain-
ing patients. The number of patients with mild and mod-
erate/severe AR in both groups was very similar whether 
severity was classified according to rTNSS and conges-
tion scores or according to the ARIA definition.
Student t tests and Wilcoxon rank-sum tests were 
used to compare continuous outcomes for the two SAR 
severities, for parametric and non-parametric data, 
respectively. Results are presented with means and stand-
ard deviations, unless significant skew was observed 
in the outcome, in which case medians are presented. 
Chi-squared tests and Fisher’s exact tests (where cell fre-
quency was less than 5) were used to compare categori-
cal outcomes to investigate differences between the two 
SAR severities and results presented as frequencies and 
percentages. Odds ratios were calculated for moderate/
severe versus mild SAR for a given exposure with refer-
ence to no exposure. For all analyses p values <0.05 were 
judged to be statistically significant.
Results
Survey response
The survey was sent to 1300 potential participants. Data 
collection was stopped once 1000 patients completed the 
survey.
Demographic and socioeconomic characteristics
One thousand SAR patients were recruited (mild: 
n = 254; moderate/severe: n = 746). The average age was 
42.6 [standard deviation (SD) 12.1] years, with female 
gender and white ethnicity predominating (Table  1). 
Most participants were in full or part-time employ-
ment or self-employed (69.1 %), with over three quarters 
(76.9  %) educated to A-level standard (i.e. international 
baccalaureate level or above).
Sensitization pattern
Grass and tree pollen were the most commonly reported 
sensitizing allergens, but indoor allergen (e.g. to animal 
dander, mites) and mould sensitization was also com-
mon. A high level of polysensitization was apparent 
particularly in the moderate/severe group (Table 1). Sig-
nificantly (p < 0.001) more patients with moderate/severe 
disease were aware of their sensitizing allergen (Table 1).
Episode pattern and duration
Patients with moderate/severe AR experienced signifi-
cantly more symptomatic episodes/year than those with 
mild disease (median 8.0 vs 6.0; p  =  0.025) with each 
of these episodes lasting significantly longer (12.5 vs 
9.8 days; p = 0.0041; Table 1).
Medication usage
Almost all patients reported taking medication to treat 
their rhinitis symptoms (90.6 and 96.2  % of patients 
with mild and moderate/severe AR, respectively). Oral 
H1-antihistamines were the medications most com-
monly reported, followed by INS (Table 2). Patients with 
moderate/severe AR were more likely to report nasal 
spray use (66.7 %) than those with mild disease [58.3 %; 
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odds ratio (OR) 1.44; 95 % confidence interval (CI) 1.05–
1.97; p =  0.0196]. One-third of patients in both groups 
used ocular medication (Table 2). Only 0.9 and 1.7 % of 
patients with mild or moderate/severe disease, respec-
tively, reported use of injections (either immunotherapy 
or systemic corticosteroids) to treat their AR.
Most patients reported the use 2 or more AR medi-
cations (56.1 % of patients with mild AR and 70.5 % of 
patients with moderate/severe AR), but were nearly 
twice as likely to do so if they had moderate/severe dis-
ease (OR: 1.87; 95 % CI 1.36–2.56; p = 0.0001) (Table 2). 
The search for better nasal symptom relief, was the 
most common reason reported by patients for taking 2 
or more AR medications. This was particularly evident 
in the moderate/severe group, where 58.3 % of patients 
cited the need for more effective nasal treatment as the 
reason for co-medicating compared to 42.6  % of those 
with mild AR (OR 1.88; 95 % CI 1.25–2.84; p = 0.0014) 
(Table  2). More effective ocular symptom relief was 
another important determinant governing co-prescrib-
ing behaviour, reported by over 40 % of patients in both 
groups (Table  2). This was in line with the proportion 
of patients who reported ocular medication use (mild: 
31.3  %; moderate/severe: 38.3  %). The search for faster 
response also drove AR treatment choice, with almost 
35 % of patients with moderate/severe AR citing this as 
their reason for co-medicating (Table 2).
Symptom burden
The symptom burden reported by these patients 
was high, even though over 90  % of them were tak-
ing an AR medication. On the day of assessment, par-
ticipants in both severity groups reported significant 
nasal and ocular symptoms. However, this burden 
(both nasal and ocular) was significantly higher in 
those with moderate/severe disease (Fig.  1). Patients 
with moderate/severe disease also reported a signifi-
cantly (p < 0.0001) higher overall nasal symptom bur-
den when symptoms were at their worst (10.0 [SD 1.5] 
vs 5.9 [SD 1.9]).
On the day of assessment (June–July 2011), many 
patients were experiencing ‘moderate’ or ‘severe’ nasal itch, 
Table 1 Participant demographic and baseline data
SAR severity: participants with moderate/severe AR were defined as those who scored a rTNSS ≥8 out of 12, including a congestion score ≥2/3, when describing their 
‘worst symptoms’. Participants with mild AR included all remaining patients
SD standard deviation
Allergic rhinitis severity p value
Mild (n = 254) Moderate/severe (n = 746)
Age, mean (sd) 44.1 (13.0) 42.1 (11.8) 0.0274
Gender, n (%) female 175 (68.9) 503 (67.4) 0.665
Ethnicity, n (%)
White 226 (89.0) 666 (89.3) 0.894
Asian 16 (6.3) 41 (5.5) 0.633
Black 3 (1.2) 25 (3.4) 0.070
Mixed 5 (2.0) 5 (0.7) 0.072
No response 4 (1.6) 9 (1.2) 0.654
Allergen sensitivity (self-reported)
Grass pollen 165 (65.0) 579 (77.6) <0.001
Tree pollen 119 (46.9) 462 (61.9) <0.001
Weed pollen 56 (22.0) 259 (34.7) <0.001
Animals 57 (22.4) 231 (31.0) <0.001
Mites 29 (11.4) 163 (21.8) <0.001
Moulds 25 (9.8) 152 (20.4) <0.001
Not sure 57 (22.4) 96 (12.9) <0.001
Other 25 (9.8) 83 (11.1) 0.569
No. symptom episodes/year, median 6.0 8.0 0.025
No. days/episode
Mean (SD) 9.8 (18.1) 12.5 (20.2) 0.0041
Median 4.0 5.0 0.013
Asthma diagnosis, n (%) 70 (30.4) 257 (35.8) 0.1368
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congestion, rhinorrhea and sneezing as well as ocular itch, 
watering and redness, despite treatment, with significantly 
more patients with moderate/severe AR experiencing 
greater symptom severity for each nasal and ocular symp-
tom (Table  3; Fig.  2). Congestion appeared to be the most 
bothersome nasal symptom; with 61.5  % of participants 
with moderate/severe AR rating its severity as ‘moderate’ or 
‘severe’ on the day of assessment compared to 33.5 % of those 
with mild disease (Fig.  2). Ocular itch was the most both-
ersome ocular symptom; 59.4  % patients with moderate/
Table 2 Medication usage in mild and moderate/severe seasonal allergic rhinitis patients
SAR severity: paricipants with moderate/severe AR were defined as those who scored a rTNSS ≥8 out of 12, including a congestion score ≥2/3, when describing their 
‘worst symptoms’. Participants with mild AR included all remaining patient
SAR seasonal allergic rhinitis, CI confidence interval
SAR severity
Mild
(n = 254)
Moderate/severe (n = 746) Odds ratio (95 % CI) P value
Taking medication, n (%) 230 (90.6) 718 (96.2) 2.68 (1.45, 4.89) 0.0004
Oral medications, n (%) 184 (80.0 %) 605 (84.3 %) 1.34 (0.89, 1.98) 0.1322
Cetirizine 82 (44.6) 313 (51.7) 1.33 (0.94, 1.89) 0.0885
Loratadine 61 (33.2) 195 (32.2) 0.96 (0.67, 1.39) 0.8153
Chlorphenamine 61 (33.2) 178 (29.4) 0.84 (0.58, 1.22) 0.3349
Pseudoephedrine 14 (7.6) 92 (15.2) 2.18 (1.19, 4.25) 0.0081
Phenylephrine 7 (3.8) 33 (5.5) 1.46 (0.62, 3.97) 0.3716
Acrivastine 20 (10.9) 82 (13.6) 1.29 (0.75, 2.28) 0.3420
Levocetirizine 0 (0) 19 (3.1) – 0.011
Fexofenadine 10 (5.4) 38 (6.3) 1.17 (0.56, 2.68) 0.6741
Desloratadine 3 (1.6) 24 (4.0) 2.49 (0.74, 13.06) 0.1651
Other 17 (9.2) 57 (9.4) 1.02 (0.57, 1.93) 0.9408
Nasal sprays, n (%) 134 (58.3 %) 479 (66.7 %) 1.44 (1.05, 1.97) 0.0196
Fluticasone propionate 96 (71.6) 338 (70.6) 0.95 (0.60, 1.47) 0.8083
Beclomethasone 33 (24.6) 110 (23.0) 0.91 (0.57, 1.48) 0.6875
Mometasone 4 (3.0) 31 (6.5) 2.25 (0.77, 8.92) 0.1241
Fluticasone furoate 4 (3.0) 12 (2.5) 0.89 (0.26, 3.84) 0.8401
Flunisolide 1 (0.8) 12 (2.5) 3.42 (0.50, 147.15) 0.2116
Budesonide 2 (1.5) 10 (2.1) 1.41 (0.29, 13.36) 0.6602
Ipratropium bromide 0 (0) 5 (1.0) – 0.29
Other 18 (13.4) 48 (10.0) 0.72 (0.39, 1.36) 0.2600
Oxymetazoline 9 (6.7) 39 (8.1) 1.23 (0.57, 2.97) 0.5871
Azelastine 25 (18.7) 106 (22.1) 1.23 (0.75, 2.10) 0.3860
Ocular medications, n (%) 72 (31.3 %) 275 (38.3 %) 1.36 (0.98, 1.90) 0.0552
Sodium cromoglicate 14 (19.4) 82 (29.8) 1.76 (0.91, 3.61) 0.0798
Antazoline 12 (16.7) 50 (18.2) 1.11 (0.54, 2.44) 0.7651
Xylometazoline 9 (12.5) 36 (13.1) 1.05 (0.47, 2.62) 0.8943
Azelastine 3 (4.2) 13 (4.7) 1.14 (0.30, 6.41) 0.8400
Olopatadine 3 (4.2) 17 (6.2) 1.52 (0.42, 8.29) 0.5137
Lodoxamide trometamol 1 (1.4) 9 (3.3) 2.40 (0.32, 106.74) 0.3950
Other 33 (45.8) 98 (35.6) 0.65 (0.37, 1.15) 0.1121
Co-medicating, n (%) 129 (56.1) 506 (70.5) 1.87 (1.36, 2.56) 0.0001
Reported reason for co-medicating, n (%)
 More effective nasal treatment 55 (42.6) 295 (58.3) 1.88 (1.25, 2.84) 0.0014
 More effective ocular treatment 54 (41.9) 209 (41.3) 0.98 (0.65, 1.48) 0.9089
 Faster nasal response 22 (17.1) 116 (22.9) 1.45 (0.86, 2.52) 0.1490
 Faster ocular 13 (10.1) 57 (11.3) 1.13 (0.59, 2.33) 0.7007
 Other 18 (19.0) 48 (9.5) 0.65 (0.35, 1.23) 0.1378
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severe AR rated its severity as ‘moderate’ or ‘severe’ on the 
day of assessment compared to 39.7 % of those with mild AR 
(Fig. 2).
Health care visits
Participants with moderate/severe AR reported visit-
ing their GP for their SAR more frequently than those 
with mild AR (1.61 vs 1.19 times/year; OR 1.49; 95 % CI 
1.11–2.01; p  =  0.0061). In both groups, dissatisfaction 
with treatment was a primary reason for the visit; 28 % 
of visits for patients with mild AR versus 35  % of visits 
for those with moderate/severe disease, with patients 
with moderate/severe AR being significantly more likely 
to report treatment dissatisfaction than those in the mild 
group (OR 1.49; 95 % CI 1.06–2.13; p = 0.0194).
Impact on asthma
Many AR participants reported co-morbid asthma; 
30.4 and 35.8  % of participants with mild and moder-
ate/severe AR, respectively, and reported modifying 
their asthma medication (both reliever and controller) 
if they failed to take their AR medication. Patients with 
moderate/severe AR were twice as likely to describe 
this behaviour. For asthma reliever medication, 45.7 % 
of patients with mild AR with co-morbid asthma 
(n = 70) reported increased use compared to 53.7 % of 
patients with moderate/severe AR (n = 257) (OR 1.93; 
95  % CI 1.01–3.68; p  =  0.0303). Similarly, 15.7  % of 
patients with mild AR with co-morbid asthma reported 
the need to increase their controller medication if they 
failed to take their AR medication, rising to 19.5  % of 
patients in the moderate severe group (OR 2.04; 95  % 
CI 0.86–5.03; p = 0.0781).
Absenteeism and presenteeism
Patients with moderate/severe AR reported absenteeism 
from work due to their SAR on 4.1 (SD 16.4) days/year 
compared to 2.5 (SD 7.7) days/year for patients in the mild 
group (OR: 1.34; 95 % CI: 0.87-2.11; p = 0.1708). This was 
significantly more likely for patients with moderate/severe 
AR who reported 37.7 (SD 53.0) days/year when their 
productivity was affected by their SAR symptoms, almost 
double that noted by patients with mild disease (21.0 days 
[SD 29.9]; OR: 1.71; 95 % CI: 1.15-2.54; p = 0.0048).
Participants with mild AR did report some negative 
impact on their productivity, clustered predominantly at 
the lower impact end of the productivity scale (i.e. < 50 % 
impact). The negative impact on participant-reported 
work productivity due to SAR symptoms was much 
more apparent for those with moderate/severe disease. 
These patients were almost 4 times more likely to experi-
ence > 50 % negative impact on their work productivity 
than those with mild disease (32.8 % vs 12.2 %; OR: 3.52; 
95 % CI: 2.10-6.13; p < 0.0001) (Fig. 3).
Discussion
This study provides a comprehensive view of the AR bur-
den and unmet need in the UK. A complete dataset has 
been collected from a medically- diagnosed, symptomatic, 
SAR patient population (of similar disease severity to those 
included in a recent SAR study) [39] including information 
on SAR episode pattern and duration, medication/co-medi-
cation usage, reasons for co-medication, residual symptoms 
on treatment, number of healthcare visits, absenteeism and 
productivity loss in patietns with mild and moderate/severe 
AR. It, therefore, represents a complete assessment of AR 
burden and unmet need in a single survey.
This was a relatively large survey, including 1000 AR 
patients with wide representation of age, educational 
level and employment status. Survey content was broad 
and informed by several world-renowned experts in the 
field of AR. As this was an online survey, there was no 
interviewer bias. Responders were free to answer the 
questions in a time convenient to them and at their own 
pace. Patients were initially screened for severity using 
the Allergic Rhinitis and its Impact on Asthma (ARIA) 
severity classification system yielding 200 patients with 
mild AR and 800 patients with moderate/severe AR to 
ensure adequate representation of patients with moder-
ate/severe AR in the survey (i.e. patients most likely to 
Fig. 1 Nasal and ocular symptom burden reported by seasonal aller-
gic rhinitis patients with mild (n = 254) or moderate/severe disease 
(n = 746) on the day of assessment. Over 90 % of these patients in 
both groups were taking AR medication (see Table 2). Data are pre-
sented as mean and standard deviation. rTNSS: reflective total nasal 
symptom score (max = 12); rTOSS: reflective total ocular symptom 
score (max = 9). *p < 0.0001 vs mild AR
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visit their healthcare provider). However, to align with 
moderate/severe definition commonly employed in AR 
clinical trials, severity was also classified using rTNSS 
and congestion score cut offs for the purpose of data 
analysis. Very similar numbers were reported using this 
method of categorization; 254 and 746 for patients with 
mild and moderate/severe AR, respectively. This con-
firms the robustness of the ARIA severity definition as a 
quick, simple and accurate method of severity categori-
zation, and also that the moderate/severe definition used 
in the present analysis largely conforms to ARIA.
Although the data relates to the UK in terms of aller-
gen exposure, as well as treatment and referral patterns, 
the results also have a broader relevance for clinical trial 
design in general. For example, knowledge of the dura-
tion of a typical mild and moderate/severe SAR symp-
tom episode could inform trial duration decisions and 
also encourage contextualization of efficacy endpoints 
with a temporal focus. A potential limitation of this sur-
vey was that patients were recruited from a patient panel. 
These panels include a varied and heterogeneous patient 
population. Panel patients are not subjected to stringent 
Table 3 Nasal and ocular symptom burden of patients with mild and moderate/severe AR on the day of assessment
SAR severity: paricipants with moderate/severe AR were defined as those who scored a rTNSS ≥8 out of 12, including a congestion score ≥2/3, when describing their 
‘worst symptoms’. Participants with mild AR included all remaining patients
Symptom severity: Assessed by individual symptom scores of the rTNSS and rTOSS; 0 = none, 1 = mild, 2 = moderate, 3 = severe
SAR seasonal allergic rhinitis, rTNSS reflective total nasal symptom score, rTOSS reflective total ocular symptom score
Symptom Symptom severity SAR severity P value
Mild (n = 254) Moderate/severe (n = 746)
Nasal symptoms of the rTNSS
Nasal itch, n (%) None 63 (24.8) 87 (11.7) <0.001
Mild 128 (50.4) 298 (39.9) 0.004
Moderate 54 (21.3) 283 (37.9) <0.001
Severe 9 (3.5) 78 (10.5) 0.001
Nasal congestion, n (%) None 67 (26.4) 61 (8.2) <0.001
Mild 102 (40.2) 226 (30.3) 0.004
Moderate 67 (26.4) 312 (41.8) <0.001
Severe 18 (7.1) 147 (19.7) <0.001
Rhinorrhea, n (%) None 82 (32.3) 111 (14.9) <0.001
Mild 102 (40.2) 241 (32.3) 0.023
Moderate 56 (22.0) 279 (37.4) <0.001
Severe 14 (5.5) 115 (15.4) <0.001
Sneezing, n (%) None 55 (21.7) 68 (9.1) <0.001
Mild 108 (42.5) 256 (34.3) 0.019
Moderate 75 (29.5) 281 (37.7) 0.019
Severe 16 (6.3) 141 (18.9) <0.001
Ocular symptoms of the rTOSS
Ocular itch, n (%) None 51 (20.1) 97 (13.0) 0.006
Mild 102 (40.2) 206 (27.6) <0.001
Moderate 74 (29.1) 276 (37.0) 0.023
Severe 27 (10.6) 167 (22.4) <0.001
Ocular watering, n (%) None 70 (27.6) 154 (20.6) 0.022
Mild 102 (40.2) 220 (29.5) 0.002
Moderate 64 (25.2) 239 (32.0) 0.040
Severe 18 (7.1) 133 (17.8) <0.001
Ocular redness, n (%) None 91 (35.8) 183 (24.5) <0.001
Mild 106 (41.7) 316 (42.4) 0.861
Moderate 51 (20.1) 209 (28.0) 0.013
Severe 6 (2.4) 38 (5.1) 0.067
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inclusion/exclusion criteria and have a relaxed ecol-
ogy of care making the information they provide more 
indicative of the real world. Conversely, AR patients 
recruited into randomized controlled trials (RCTs) are 
poorly representative of those seen in primary care [40]. 
In the present study AR was classified according to time 
of year when symptoms appeared (i.e. SAR) rather than 
the ARIA classification based on symptom longevity (i.e. 
intermittent/persistent). These classifications are not 
interchangeable [1], and whilst the SAR/PAR classifica-
tion is still widely used in primary care, the newer (and 
more therapeutically relevant) ARIA classification sys-
tem should be promoted at both the patient and physi-
cian level. By design, most patients included in the survey 
had moderate/severe disease and so represent the type 
of patients who present to physicians [2, 4, 17, 23]. Also, 
patients were included in this survey based on a reported 
medical diagnosis of SAR, rather than a medically-con-
firmed diagnosis. No data were collected on irritant 
exposure or smoking history. It would have been inter-
esting to examine their impact on symptom burden and 
therapeutic response. As with all surveys of this nature 
there was a reliance on patient recall. Variability was 
noted for some responses as evidenced by large stand-
ard deviations around the mean. Where this occurred, 
median values were used.
The survey found that patients experienced several 
symptomatic bursts throughout the year, each lasting for 
some days, with participants with moderate/severe AR 
reporting significantly greater symptom episode frequency 
and duration than their milder counterparts. There was 
a clear symptom burden shift from patients with mild to 
those with moderate/severe AR, the latter, more likely to 
report more and longer episodes/year. These facts were 
previously unrecognised. The symptom burden shift pro-
vides evidence of the quality of the survey data and its 
Fig. 2 Proportion of patients with mild (n = 254) or moderate severe 
AR (n = 746) scoring a ‘2’ (moderate) or ‘3’ (severe) for individual nasal 
and ocular symptom scores on the day of assessment. Over 90 % 
of these patients in both groups were taking AR medication (see 
Table 2). Significance values for mild vs moderate/severe groups are 
given for each level of symptom severity in Table 3
Fig. 3 Presenteeism due to SAR reported by patients with mild disease (n = 164) and those with moderate/severe disease (n = 521). *p ≤ 0.0093 
vs mild AR. Patients with moderate/severe AR significantly (OR 3.52; CI 2.10–6.13; p < 0.0001) more likely than those with mild AR to have a >50 % 
impairment in their work productivity due to their SAR symptoms
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sensitivity to discriminate according to disease symptom 
severity. Knowledge of duration and frequency of AR 
symptom episodes is important to know when assessing 
the symptomatic and economic burden of AR, and when 
considering treatment choice. It indicates that rapid relief 
of symptoms is important to control the disease.
The extent to which patients co-medicate is underes-
timated by physicians and payers alike, since over the 
counter medications are frequently added to prescrip-
tion medications. This finding has also been observed in 
Spain and France [3, 26, 27]. The majority of participants 
who took part in this survey reported using 2 or more AR 
medications (most commonly an INS plus an oral H1-anti-
histamine) in an attempt to achieve better and faster nasal 
and ocular symptom relief. This was true for both the par-
ticipants with moderate/severe disease (70.5 %) and those 
with mild AR (56.1 %), although significantly more likely in 
those with more severe disease. Therefore, the direct cost 
of AR may be higher than previously thought, as patients 
supplement with multiple treatments, driven by their 
search for better efficacy. This search for a faster and more 
effective nasal therapy was more in evidence as a driver for 
those patients with moderate/severe AR emphasizing the 
higher symptom burden of this group, not only in terms of 
symptom severity, but also in terms of episode frequency 
and duration. The fact that over half of patients with mild 
AR co-medicated was an unexpected finding. This result 
showed that monotherapy provides insufficient symptom 
relief for a substantial proportion of patients with mild 
AR too, suggesting that they may underestimate the true 
severity of their disease and/or rely on over-the-counter 
AR medications, being resistant to attending their physi-
cian in order to receive a more effective treatment option, 
or indeed a more accurate severity diagnosis. Others have 
confirmed that co-mediation prescribing behaviour has 
been steadily rising in the UK in the last 2 decades; dual 
therapy has doubled since 1992, whilst use of triple ther-
apy has increased eight-fold [41].
However, co-medication does not appear to pro-
vide the symptom relief, which AR patients seek. Logi-
cally, one would assume that use of several medications 
from different classes would provide improved patho-
logic coverage leading to better symptom control. But, 
this does not appear to be the case. The present survey 
results confirm the results obtained in randomized clini-
cal trials [29, 30]. Both patients with mild and moderate/
severe AR included in this survey remained sympto-
matic, with those with more severe disease more likely to 
be so, even though > 90 % of patients were on AR treat-
ment, and many were co-medicating. In other words, 
patients’ symptoms were still of moderate severity, on 
average, despite treatment. Nasal congestion and ocular 
itching remained problematic for 60  % of patients with 
moderate/severe disease and were difficult to control 
with mono or multiple therapies. A similar pattern of 
mono- and multiple-therapy insufficiency has also been 
observed in other countries [4]. There is, therefore, a 
clear need for a faster and more effective AR treatment 
option with wide symptomatic and pathologic coverage, 
which provides more complete and rapid symptom con-
trol. MP29-02, comprising azelastine hydrochloride, flu-
ticasone propionate and a novel formulation in a single 
spray, is the newest addition to the AR treatment arse-
nal and is promising in this regard [39, 42]. Allergen-
specific immunotherapy should be strongly considered 
for patients who fail to respond to symptomatic therapy, 
particularly for those patients for whom symptoms are 
predominantly caused by one allergen [43], and may sig-
nificantly reduce the burden of AR in these patients.
This survey also serves to highlight the large indirect 
burden of AR in the UK; the hidden costs associated with 
this disease are substantial. Many patients with AR also 
have asthma, with failure to control one having a detri-
mental effect on control of the other [1]. In the present 
survey, asthma medication usage (both reliever and con-
troller) was likely to be increased by participants if they 
failed to use their AR medication, and more likely to 
occur in those with moderate/severe AR. Other indirect 
costs reported included absenteeism and presenteeism. 
On average, patients with moderate/severe AR reported 
4 days/year absent from work due to their SAR. Assum-
ing an average cost of £71 for each lost day [44], this 
amounts to £1.14 billon/year in the UK alone. This figure 
does not take presenteeism into consideration, which was 
reportedly negatively impacted on 38 days/year and car-
ries a substantial indirect cost [19].
Knowledge of AR symptom patterns is vital when con-
sidering relevancy of clinical trial data and appropriate-
ness of clinical trial design. Patients with intermittent 
AR (as categorized by ARIA) experience symptoms for 
<4  days/week or for less than 4 consecutive weeks [1]. 
Based on the results presented here, we now have cor-
responding information for SAR (i.e. average symptom 
episode lasts 9.8 days for mild SAR and 12.5 days for mod-
erate/severe SAR). Therefore, SAR trials of 14 days dura-
tion are sufficiently long to assess the clinical efficacy of 
medications in most patients; since this timeframe spans 
a single episode, and thus reflects the real-world situation. 
Additionally, any improvements afforded by AR medica-
tions in patients with moderate/severe AR should now be 
contextualized and assessed for clinical relevancy within 
a 12.5 day time frame. It is also clear that direct head-to-
head trials of active comparators are needed, not simply 
comparisons versus placebo, since the vast majority of 
patients with moderate/severe AR are treated, and most 
are co-medicating. Therefore, studies versus placebo 
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only, in those patients with moderate/severe disease are 
not clinically-relevant, may provide a distorted view of 
the effectiveness of active comparators, and are likely to 
increase the number of insufficiently effective drugs reg-
istered, failing to meet patient expectations of treatment. 
The results of our study support the request of ARIA to 
conduct clinical trials against gold standard therapy in 
order to show clinically relevant improvements that will 
lower the burden of AR and improve its management. A 
recently published state of the art analysis of a new AR 
therapy, is an important first step in this direction [39]; 
(1) patients included in the trial had moderate/severe dis-
ease, representing the type of patient commonly seen in 
practice, (2) first-line AR medications were used as active 
comparators (in addition to placebo), (3) results were 
contextualised within a typical symptom episode win-
dow and (4) data were analysed to show not only superior 
efficacy to established first line therapies but also a faster 
response, which is what patients want [33, 45].
The impact of patients’ attitudes on their AR health 
outcomes and their decision processes when considering 
which AR medication to take are interesting avenues for 
additional research. More information on patient knowl-
edge (both about the disease and available treatments) 
as well as incidence of co-morbidities (e.g. food allergy, 
asthma, atopic dermatitis) would also provide a more 
global look at burden of care. Finally, patients should be 
empowered to take responsibility for their own AR con-
trol, encouraged to improve their disease awareness and 
knowledge of AR therapeutic options and improve con-
cordance with their treatment regimen. In this regard, 
the importance of a common AR control concept and 
language (for both patients and physicians) has been rec-
ognized [46]. MACVIA ARIA has recently launched an 
app, called Allergy Diary, which uses a simple visual ana-
logue scale (VAS) to assess control and will use this same 
VAS in an app for health care providers (called Allergy 
Diary Companion) and in the updated guideline to guide 
AR treatment decisions [46].
Conclusions
This cross-sectional online questionnaire-based study 
represents a comprehensive assessment of the burden 
and unmet need of AR in the UK in a large patient popu-
lation. Knowledge of the results of study should be used 
to inform clinical trial design and relevancy of clinical 
findings, and to assess the potential impact of AR treat-
ments on the true burden and unmet need in this highly 
prevalent condition.
Additional file
Additional file 1. Socio-demographic/healthcare utilisation questions.
Abbreviations
AR: allergic rhinitis; ARIA: allergic rhinitis in asthma; CI: confidence interval; 
INS: intranasal corticosteroid; OR: odds ratio; RCT: randomized controlled 
trial; rTNSS: reflective total nasal symptom score; rTOSS: reflective total ocular 
symptom score; SAR: seasonal allergic rhinitis; SCUAD: severe chronic upper 
airway disease; SD: standard deviation; WPAI: work productivity and activity 
impairment.
Authors’ contributions
All authors have been involved in the analysis and interpretation of data. 
SA and RP also contributed to the conception and design of the survey. All 
authors were involved in the drafting of the manuscript, critically revised each 
draft and gave their final approval for publication. All authors agree to be 
accountable for all aspects of this work and have participated sufficiently to 
take public responsibility for the content. All authors read and approved the 
final manuscript.
Authors’ information
DP is Professor of Primary Care Respiratory Medicine at the University of 
Aberdeen, co-founder of the Respiratory Effectiveness Group (http://www.
effectivenessevaluation.org) and Director of Observational and Pragmatic 
Research Institute Singapore. GS is Hon. Consultant Rhinologist and Allergist at 
the Royal National TNE Hospital, London and Hon. Senior Lecturer at University 
College, London. DR has had a career-long interest in respiratory allergy and 
was twice chairman of the UK Primary Care Respiratory Society. He is a mem-
ber of ARIA and current Chairman of the Primary care Interest Group of EAACI. 
CB is an ENT specialist and allergologist at the Ghent University Hospital, and 
runs the Upper Airways Research Laboratory, Ghent University. He is also affili-
ated with the Karolinska Institute in Stockholm, Sweden. GWC is Professor of 
Respiratory Medicine and Director of Allergy & Respiratory Disease Clinic, Dept 
Internal Medicine, University of Genoa, IRCCS AOU San Martino, Genoa Italy. 
JM is an ENT specialist and Director of the Rhinology Unit and Smell Clinic, 
ENT Department, Hospital Clínic de Barcelona; and Professor of Research and 
Head of the Laboratory Clinical and Experimental Respiratory Immunoallergy 
at IDIBAPS. Barcelona, Catalonia, Spain. LK is Director of the Center for Rhinol-
ogy and Allergology, Wiesbaden, Germany (http://www.Allergiezentrum.org), 
Vice-President of the German Academy of Allergology and Clinical Immunol-
ogy, Vice-President of the German Union of Allergologists and Professor at Hei-
delberg University, Germany. RP is an employee of Icon plc. SA is the director 
of a Clinical Outcomes Assessment research consultancy. RM is the director of 
a Medical and Scientific research consultancy. JB is a Professor Emeritus at the 
University of Montpellier in France. He is recognized as past chairman of the 
Global Initiative for Asthma (GINA) and as the founder and Chairman of ARIA 
(Allergic Rhinitis and its Impact on Asthma), in collaboration with the World 
Health Organization. Prof Bousquet is also past Chairman of the WHO Global 
Alliance Against Chronic Respiratory Diseases (GARD), Director of the WHO 
Collaborating Centre for Asthma and Rhinitis in Montpellier, and coordinator 
of several projects of the European Union in research, health and ICT. Professor 
Bousquet’s current interests lie with the European Innovation Partnership 
on Active and Health Aging, and updating how chronic diseases like allergic 
rhinitis are managed using an integrated care pathway.
Author details
1 University of Aberdeen, Aberdeen, UK. 2 The Royal National Throat, Nose 
and Ear Hospital, London, UK. 3 Woodbrook Medical Centre, Loughborough, 
UK. 4 University of Edinburgh, Edinburgh, UK. 5 Upper Airways Research 
Laboratory, Ghent University Hospital, Ghent, Belgium. 6 Allergy and Respira-
tory Clinic, IRCCS AOU S. Martino, Genoa, Italy. 7 Hospital Clínic, IDIBAPS, 
CIBERES, Barcelona, Catalonia, Spain. 8 Center for Rhinology and Allergology, 
Wiesbaden, Germany. 9 ICON, Oxford, UK. 10 Acaster Consulting, London, 
UK. 11 Medscript Ltd, Dundalk, Ireland. 12 University Hospital, Montpellier, 
France. 13 MACVIA-LR, Contre les Maladies Chronique spour un Vieillissement 
Actif en Languedoc Roussilon, European Innovation Partnership on Active 
and Healthy Ageing Reference Site, Montpellier, France. 14 INSERM, VIMA : 
Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, 
U1168, Paris, France. 15 UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-
Yvelines, Versailles, France. 
Acknowledgements
We thank Icon Plc for statistically analysing the results.
Page 11 of 12Price et al. Clin Transl Allergy  (2015) 5:39 
Funding
Funding for this survey was provided by Meda Pharma.
Previous data presentation at conferences
Some of the data presented within this article have been presented at the 
European Academy of Allergy Clinical Immunology Congress (2012 and 2013).
Competing interests
DB has Board Membership with Aerocrine, Almirall, Amgen, AstraZeneca, 
Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and 
Teva. Consultancy: A Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, 
Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, and 
Teva; Grants and unrestricted funding for investigator-initiated studies from 
UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, 
Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmith-
Kline, Meda, Merck, Mundipharma, Napp, Novartis, Orion, Pfizer, Respira-
tory Effectiveness Group, Takeda, Teva, and Zentiva; Payments for lectures/
speaking: Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoS-
mithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, 
Takeda, and Teva; Payment for manuscript preparation: Mundipharma 
and Teva; Patents (planned, pending or issued): AKL Ltd.; Payment for the 
development of educational materials: GlaxoSmithKline, Novartis; Stock/
Stock options: Shares in AKL Ltd which produces phytopharmaceuticals 
and owns 80 % of Research in Real Life Ltd and its subsidiary social enter-
prise Optimum Patient Care; received Payment for travel/accommodations/
meeting expenses from Aerocrine, Boehringer Ingelheim, Mundipharma, 
Napp, Novartis, and Teva; Funding for patient enrolment or completion 
of research: Almirral, Chiesi, Teva, and Zentiva; and Peer reviewer for grant 
committees: Medical Research Council (2014), Efficacy and Mechanism 
Evaluation programme (2012), HTA (2014). GS has received research grants 
from GSK and ALK as well as honoraria for articles, consulting, lectures/
chairing and/or advisory boards from ALK, Bausch & Lomb, Church & 
Dwight, Circassia, GSK, Groupo Uriach, Meda, Merck, Ono, Shionogi and 
Stallergenes. DS has been paid consultancy fees by Stallergenes, Uriach 
and TEVA. He has lectured on behalf of MEDA, GSK, AZ, Chiesi, Thermo-
Fisher, Boehringer, Novartis and Almirall. He is Director of Health Strategy 
at Optimum Patient Care. CB is on the speaker’s bureau for Meda. GWC has 
received honoraria for lectures or scientific advisory boards: ALK, Allergy 
Therapeutics, AstraZeneca, Boston Scientific, Bruschettini, Chiesi, Circassia, 
Faes, GSK, Meda, Menarini, Mundifarma, Novartis, Recordati, Roche, Sanofi-
Aventis, Uriach, Stallergènes, Thermo Fisher, Teva and Valeas. JM is or has 
been a member of national and international scientific advisory Boards 
(consulting), received fees for lectures, or grants for research projects from 
ALK-Abelló, Boheringer-Ingelheim, FAES, GSK, Hartington Pharmaceuticals, 
Hyphens, Johnson & Johnson, MEDA Pharma, Menarini, MSD, Novartis, 
Pierre Fabre, Sanofi, UCB, and Uriach Group. LK has received research grants 
from ALK-Abelló, Allergopharma, Bionorica, Dr. Pfleger, Stallergenes, HAL, 
Artu Biologicals, Allergy Therapeutics/Bencard, Hartington, Lofarma, MEDA, 
MSD, Novartis/Leti, ROXALL, GSK, Essex-Pharma, Cytos, Curalogic, and has 
served on the speaker’s bureau for the above mentioned pharmaceuti-
cal companies. RP has no conflict of interest to report. SA was employed 
by Oxford Outcomes who were commissioned by Meda to conduct this 
research. SA now works for Acaster Consulting Ltd, which receives fees for 
research and consultancy from Meda. RM has received consultancy fees 
from GSK, Meda, MACVIA-ARIA and Research in Real life. JB has received 
honoraria for: Scientific and advisory boards: Almirall, Meda, Merck, MSD, 
Novartis, Sanofi-Aventis, Takeda, Teva, Uriach. Lectures during meetings: 
Almirall, AstraZeneca, Chiesi, GSK, Meda, Menarini, Merck, MSD, Novartis, 
Sanofi-Aventis, Takeda, Teva, Uriach. Board of Directors: Stallergènes.
Received: 29 June 2015   Accepted: 17 October 2015
References
 1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. 
Allergic Rhinitis and its impact on asthma (ARIA) 2008 update (in col-
laboration with the World Health Organization, GA(2)LEN and AllerGen). 
Allergy. 2008;63(Suppl 86):8–160.
 2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of 
the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25.
 3. Mullol J. A survey of the burden of allergic rhinitis in Spain. J Investig 
Allergol Clin Immunol. 2009;19:27–34.
 4. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of aller-
gic rhinitis symptoms on quality of life in primary care. Int Arch Allergy 
Immunol. 2013;160:393–400.
 5. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of aller-
gic rhinitis and quality of life: findings from a survey conducted in europe 
and the United States. World Allergy Organ J. 2008;1:138–44.
 6. Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially 
impacts patient quality of life: findings from the Nasal Allergy Survey 
Assessing Limitations. J Fam Pract. 2012;61:S5–10.
 7. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 
2007;28:3–9.
 8. European Academy of Allergy and Clinical Immunology (EAACI). Beware 
of Allergy Campaign. http://www.bewareofallergy.com. Accessed Aug 
2015.
 9. Antonescu E, Childres N, Gardini E, Grossetete F, Juvin P, Parvanova A, 
et al. Written declaration on recognising the burden of allergic disease. 
European Parliament. http://www.eaaci.org. Accessed June 2015.
 10. Samolinski B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ, et al. 
Prevention and control of childhood asthma and allergy in the EU from 
the public health point of view: Polish Presidency of the European Union. 
Allergy. 2012;67:726–31.
 11. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Inte-
grated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 
2014;44:304–23.
 12. Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The 
European Innovation Partnership on Active and Healthy Aging: the Euro-
pean Geriatric Medicine introduces the EIP on AHA Column. Eur Geriatr 
Med. 2014;5:361–2.
 13. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic 
rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8:1–9.
 14. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, 
disturbed cognitive functions and psychological well-being. Clin Exp 
Allergy. 2002;32:1310–5.
 15. Braido F, Baiardini I, Scichilone N, Musarra A, Menoni S, Ridolo E, et al. Ill-
ness perception, mood and coping strategies in allergic rhinitis: are there 
differences among ARIA classes of severity? Rhinology. 2014;52:66–71.
 16. Green RJ, Davis G, Price D. Concerns of patients with allergic rhinitis: 
the Allergic Rhinitis Care Programme in South Africa. Prim Care Respir J. 
2007;16:299–303.
 17. Mullol J, Bartra J, del CA, Izquierdo I, Munoz-Cano R, Valero A. Specialist-
based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy. 
2013;43:723–9.
 18. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al. 
Economic impact of workplace productivity losses due to allergic rhinitis 
compared with select medical conditions in the United States from an 
employer perspective. Curr Med Res Opin. 2006;22:1203–10.
 19. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis 
and the common cold–high cost to society. Allergy. 2010;65:776–83.
 20. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of 
life in patients being treated for seasonal allergic rhinitis: a cohort survey. 
Clin Transl Allergy. 2013;3:33.
 21. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal 
allergic rhinitis is associated with a detrimental effect on examination 
performance in United Kingdom teenagers: case-control study. J Allergy 
Clin Immunol. 2007;120:381–7.
 22. Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-
report assessment of adherence, rhinitis and smoking in relation to 
asthma control. Prim Care Respir J. 2009;18:300–5.
 23. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 
2007;62(Suppl 85):9–16.
 24. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al. 
Characteristics of intermittent and persistent allergic rhinitis: DREAMS 
study group. Clin Exp Allergy. 2005;35:728–32.
 25. Bachert C, Van CP, Olbrecht J, van SJ. Prevalence, classification and 
perception of allergic and nonallergic rhinitis in Belgium. Allergy. 
2006;61:693–8.
Page 12 of 12Price et al. Clin Transl Allergy  (2015) 5:39 
 26. Demoly P, Allaert FA, Lecasble M. ERASM, a pharmacoepidemiologic sur-
vey on management of intermittent allergic rhinitis in every day general 
medical practice in France. Allergy. 2002;57:546–54.
 27. Navarro A, Valero A, Rosales MJ, Mullol J. Clinical use of oral antihistamines 
and intranasal corticosteroids in patients with allergic rhinitis. J Investig 
Allergol Clin Immunol. 2011;21:363–9.
 28. Anolik R, Mometasone Furoate Nasal Spray With Loratadine Study Group. 
Clinical benefits of combination treatment with mometasone furoate 
nasal spray and loratadine vs monotherapy with mometasone furoate in 
the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 
2008;100:264–71.
 29. Ratner PH, van Bavel JH, Martin BG, Hampel FC Jr, Howland WC III, 
Rogenes PR, et al. A comparison of the efficacy of fluticasone propionate 
aqueous nasal spray and loratadine, alone and in combination, for the 
treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47:118–25.
 30. Esteitie R, deTineo M, Naclerio RM, Baroody FM. Effect of the addition of 
montelukast to fluticasone propionate for the treatment of perennial 
allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105:155–61.
 31. Hellings PW, Dobbels F, Denhaerynck K, Piessens M, Ceuppens JL, De GS. 
Explorative study on patient’s perceived knowledge level, expectations, 
preferences and fear of side effects for treatment for allergic rhinitis. Clin 
Transl Allergy. 2012;2:9.
 32. Ciprandi G, Incorvaia C, Scurati S, Puccinelli P, Soffia S, Frati F, et al. 
Patient-related factors in rhinitis and asthma: the satisfaction with allergy 
treatment survey. Curr Med Res Opin. 2011;27:1005–11.
 33. Valovirta E, Ryan D. Patient adherence to allergic rhinitis treatment: results 
from patient surveys. Medscape J Med. 2008;10:247.
 34. Mosges R, Klimek L. Today’s allergic rhinitis patients are different: new 
factors that may play a role. Allergy. 2007;62:969–75.
 35. Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy 
Asthma Immunol. 2001;86:494–507.
 36. Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al. 
Uncontrolled allergic rhinitis during treatment and its impact on quality 
of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126:666–8.
 37. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. 
Burden of allergic rhinitis: results from the Pediatric Allergies in America 
survey. J Allergy Clin Immunol. 2009;124:S43–70.
 38. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A 
novel intranasal therapy of azelastine with fluticasone for the treatment 
of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1282–9.
 39. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. 
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic 
rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 
2013;161:369–77.
 40. Costa DJ, Amouyal M, Lambert P, Ryan D, Schunemann HJ, Daures JP, 
et al. How representative are clinical study patients with allergic rhinitis in 
primary care? J Allergy Clin Immunol. 2011;127:920–6.
 41. Price D, Scadding G, Bachert C, Saleh H, Nasser S, Bichel K, et al. Dynamics 
of treatment within a year in patients diagnosed with either allergic, 
non-allergic rhinitis or hay fever over the period 1992–2012. Allergy. 
2014;69:A284.
 42. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al. Effec-
tiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results 
from a noninterventional study. Allergy Asthma Proc. 2015;36:40–7.
 43. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, 
et al. BSACI guidelines for the management of allergic and non-allergic 
rhinitis. Clin Exp Allergy. 2008;38:19–42.
 44. UK Healthcare: The case for health benefits. http://www.ukhealthcare.org.
uk/the-case-for-health-benefits. Accessed June 2015.
 45. Acaster S, Ali S, Breheny K, Bachert C, Bousquet J, Price D. Treatment 
preferences in patients with moderate/severe seasonal allergic rhinitis: 
findings of a discrete choice experiment. Allergy. 2012;67:A891.
 46. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica 
GW et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhini-
tis): The new generation guideline implementation. Allergy. 2015 [Epub 
ahead of print].
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
